Literature DB >> 3543637

Reduced phosphate reabsorption unrelated to parathyroid hormone after renal transplantation: implications for the pathogenesis of hyperparathyroidism in chronic renal failure.

A M Parfitt, M Kleerekoper, C Cruz.   

Abstract

We measured nephrogenous cyclic adenosine monophosphate (NcAMP) excretion, an in vivo bioassay for endogenous parathyroid hormone (PTH) secretion, and renal phosphate threshold (TmP/GFR) in 33 renal allograft recipients with stable renal function (creatinine clearance greater than or equal to 60 ml/min/1.73 m2 body surface area, 6 months or more post-transplant) and in 9 kidney donors. Sixteen patients had normal parathyroid function, 8 had hypercalcemic hyperparathyroidism and 9 had normocalcemic hyperparathyroidism; the latter were apparently resistant to the hypercalcemic actions of endogenous PTH, but the cause for this was not apparent. In all four subject groups, TmP/GFR was significantly and similarly lower (by 0.8-1.0 mg/dl) than predicted by multiple regression on age, sex, corrected plasma calcium and NcAMP (determined in 306 subjects spanning a wide range of parathyroid function) indicating a major PTH-independent mechanism for reducing phosphate reabsorption in the presence of a single kidney. In all four groups the contribution of this mechanism to the observed depression of TmP/GFR was substantially greater than the contribution of increased PTH secretion. In all groups, but more so in the recipients than in the donors, fasting urinary phosphate excretion/GFR was increased, so that fasting plasma phosphate, although reduced, did not accurately reflect the severity of the defect in phosphate reabsorption. We conclude that the dominant mechanism for the adaptive decrease in renal tubular phosphate transport in response to nephron reduction does not require the participation of PTH and is manifest in the presence of fasting hypophosphatemia.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3543637

Source DB:  PubMed          Journal:  Miner Electrolyte Metab        ISSN: 0378-0392


  7 in total

Review 1.  Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation.

Authors:  Wacharee Seeherunvong; Myles Wolf
Journal:  Pediatr Transplant       Date:  2010-10-08

Review 2.  Disorders of phosphate homeostasis and tissue mineralisation.

Authors:  Clemens Bergwitz; Harald Jüppner
Journal:  Endocr Dev       Date:  2009-06-03

Review 3.  FGF23 and syndromes of abnormal renal phosphate handling.

Authors:  Clemens Bergwitz; Harald Jüppner
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

Review 4.  Clinical practice. Fibroblast growth factor (FGF)23: a new hormone.

Authors:  Uri S Alon
Journal:  Eur J Pediatr       Date:  2010-12-31       Impact factor: 3.183

Review 5.  Post-renal transplantation hypophosphatemia.

Authors:  Khashayar Sakhaee
Journal:  Pediatr Nephrol       Date:  2009-07-15       Impact factor: 3.714

Review 6.  Endocrine and metabolic abnormalities following kidney transplantation.

Authors:  W H Hörl; W Riegel; C Wanner; M Haag-Weber; P Schollmeyer; H Wieland; H Wilms
Journal:  Klin Wochenschr       Date:  1989-09-01

7.  FGF23 is associated with early post-transplant hypophosphataemia and normalizes faster than iPTH in living donor renal transplant recipients: a longitudinal follow-up study.

Authors:  Narayan Prasad; Akhilesh Jaiswal; Vikas Agarwal; Shashi Kumar; Saurabh Chaturvedi; Subhash Yadav; Amit Gupta; Raj K Sharma; Dharmendra Bhadauria; Anupama Kaul
Journal:  Clin Kidney J       Date:  2016-07-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.